L-Type Calcium Channels Contribute to the Tottering Mouse Dystonic Episodes

DANIEL B. CAMPBELL and ELLEN J. HESS
Department of Neuroscience and Anatomy, Pennsylvania State University College of Medicine, Hershey, Pennsylvania

Received June 19, 1998; accepted October 2, 1998

This paper is available online at http://www.molpharm.org

ABSTRACT

Tottering mice inherit a recessive mutation of the calcium channel α1A subunit that causes ataxia, polyspike discharges, and intermittent dystonic episodes. The calcium channel α1A subunit gene encodes the pore-forming protein of P/Q-type voltage-dependent calcium channels and is predominantly expressed in cerebellar granule and Purkinje neurons with moderate expression in hippocampus and inferior colliculus. Because calcium misregulation likely underlies the tottering mouse phenotype, calcium channel blockers were tested for their ability to block the motor episodes. Pharmacologic agents that specifically block L-type voltage-dependent calcium channels, but not P/Q-type calcium channels, prevented the inducible dystonia of tottering mutant mice. Specifically, the dihydropyridines nimodipine, nifedipine, and nitrendipine, the benzothiazepine diltiazem, and the phenylalkylamine verapamil all prevented restraint-induced tottering mouse motor episodes. Conversely, the L-type calcium channel agonist Bay K8644 induced stereotypic tottering mouse dystonic at concentrations significantly below those required to induce seizures in control mice. In situ hybridization demonstrated that L-type calcium channel α1C subunit mRNA expression was up-regulated in the Purkinje cells of tottering mice. Radioligand binding with [3H]nitrendipine also revealed a significant increase in the density of L-type calcium channels in tottering mouse cerebellum. These data suggest that although a P/Q-type calcium channel mutation is the primary defect in tottering mice, L-type calcium channels may contribute to the generation of the intermittent dystonia observed in these mice. The susceptibility of L-type calcium channels to voltage-dependent facilitation may promote this abnormal motor phenotype.

Neurological mutants of the mouse are important tools for studying central nervous system development and provide models of human disease. For many of these mutants, the mutation has been identified but the mechanism by which the mutation causes the abnormal phenotype is unclear. Defining the cellular and neural systems affected by the mutation is necessary for understanding the mutant phenotype in the mouse and for applying the model to human disease states.

The neurological mouse mutation tottering (gene symbol: tgr) causes spike and wave discharges (Noebels and Sidman, 1979), ataxia, and abnormal motor episodes characteristic of intermittent dystonia (Green and Sidman, 1962). The most extensively studied of these phenotypes is the spike and wave discharge, nonconvulsive bilaterally synchronous epileptic bursts recorded by electroencephalogram. This phenotype is associated with hyperarborization of locus ceruleus axons in tottering mutants (Levitt and Noebels, 1981) as selective lesion of these axons with 6-hydroxydopamine dramatically reduced the spike and wave discharges (Noebels, 1984). By contrast, the intermittent dystonic episodes of tottering mice are neither associated with an abnormal electroencephalographic pattern (Kaplan et al., 1979; Noebels and Sidman, 1979) nor prevented by 6-hydroxydopamine lesion (Noebels, 1984). Although this abnormal motor phenotype of tottering mice is the most behaviorally obvious, the intermittent dystonic episodes have not been well characterized.

Tottering dystonic episodes are highly stereotyped, with the first observable characteristic being extension of the hindlimbs. This initial phase is followed by abduction at the hip and extension at the knee, ankle, and paw with a stiffly arched back that presses the perineum against the cage bottom. The motor dysfunction then spreads to involve the forelimbs and head, with severe flexion of the neck. In the final phase, the mice regain control of the hindlimbs, often rearing, while forepaw and facial muscles continue contractions (Green and Sidman, 1962). The entire episode lasts 30 to 60 min without loss of consciousness.

The molecular basis of the tottering mouse phenotypes was identified recently as a point mutation within the voltage-dependent calcium channel α1A subunit (Fletcher et al., 1996). Simultaneous with the identification of the tottering gene defect, the mutations underlying the human disorders familial hemiplegic migraine and episodic ataxia type-2 were

ABBRVIATIONS: SSC, standard saline citrate; DTT, dithiothreitol; ANOVA, analysis of variance.

Financial support for this research was provided by Public Health Service Grants NIH NS33592 and NIH NS34845, the Klingenstein Foundation, and the Epilepsy Foundation of America. Portions of this work were presented previously in abstract form (Society for Neuroscience Abstracts 23:2418).

identified as mutations in the human voltage-dependent calcium channel α1A subunit (Ophoff et al., 1996). Voltage-dependent calcium channels consist of four subunits: α1, α2, β, and γ. The α1 subunit is the pore-forming protein, conferring ion selectivity and voltage sensitivity; the other subunits influence the kinetic properties of the channel. Six types of voltage-dependent calcium channels have been distinguished by electrophysiology and pharmacology: L, P, Q, N, R, and T; a multiplicity of genes and alternative splice sites encode the α1 subunits of the functionally defined channels. All the voltage-dependent calcium channel α1 subunits have a similar membrane topology with four repetitive domains (I–IV), each consisting of six transmembrane segments (S1–S6) (for reviews see Catterall, 1995; Wheeler et al., 1995). The α1A subunit gene encodes P- and/or Q-type calcium channels, which are distinguished from other types of calcium channels by their sensitivity to blockade by ω-agatoxin-IVA and ω-agatoxin-TK. The tottering missense mutation results in a proline-to-leucine substitution at amino acid 601, within the extracellular loop between S5 and S6 in repetitive domain I1 of the calcium channel (Fletcher et al., 1996). Although the functional significance of this mutation is not yet known, the region in which the mutation lies is thought to be important in ion selectivity (Catterall, 1995).

Calcium misregulation resulting from the calcium channel mutation is a likely cellular mechanism underlying the abnormal phenotypes of tottering mice. Therefore, calcium channel blockers were tested for their ability to block the intermittent dystonic episodes in tottering mice. The only specific P/Q-type calcium channel antagonists currently available are the spider toxins ω-agatoxin IVA and ω-agatoxin-TK, peptides with 71% identity at the amino acid level (Mintz et al., 1992; Teramoto et al., 1993). The functional significance of this mutation is not yet known, the region in which the mutation lies is thought to be important in ion selectivity (Catterall, 1995).

Materials and Methods

Mouse Mutants. C57BL/6J+/tg mice were obtained from The Jackson Laboratories and bred at the Pennsylvania State University College of Medicine to produce tottering mutants. Adult tottering mutant mice (2–12 months of age) were identified either by analysis of polymerase chain reaction (PCR) amplification of tightly linked simple-sequence-length polymorphisms in C57BL/6J+/tg x C57BL/6J−/tg cross progeny (Campbell and Hess, 1996, 1997) or by absence of oligosaccharidism at 0s (+/+) x Os (+/+ tg) cross-progeny (Campbell and Hess, 1998). Genotype was confirmed by observation of stereotyped dystonic episodes. Age- and gender-matched C57BL/6J+/t+ mice were used as controls where appropriate. All animals were drug-naïve at the beginning of the experiments. All animal procedures were in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals.

In Situ Hybridization. Tottering mutant (tg/tg), heterozygous (+/tg), and normal (+/+t) gender-matched littermates (2–3 months of age) were deeply anesthetized with carbon dioxide and sacrificed by decapitation. The brains were rapidly removed, frozen in isopentane at −20 to −40°C, and stored at −70°C. Twenty-micrometer sagittal sections were cut using a cryostat and thaw mounted on Superfrost Plus glass slides (Fisher) with each slide bearing control and mutant sections. After drying, the slide-mounted sections were again stored at −70°C until use in in situ hybridization experiments.

A cDNA specific to the calcium channel α1A subunit gene, but not other calcium channel α1 subunit genes, was generated by reverse transcription-PCR. A 554-bp DNA segment corresponding to base pairs 5736 to 6289 of the mouse calcium channel α1A subunit cDNA (GenBank U76716) was amplified and inserted into pbLueScript II SK−. A 418-bp EcoRI fragment corresponding to base pairs 8596 to 9014 of the α1C subunit 3′ untranslated region was subcloned into pbLueScript II SK−; this sequence is unique to the α1C subunit. The original clone was obtained from the I.M.A.G.E. Consortium (Lawrence Livermore National Laboratory, Livermore, CA) cDNA clone ID#AA462894 (Lennon et al., 1996). The α1B subunit cDNA (residues 2803–3246) subcloned in pGEM was a generous gift from Dr. Hemin Chin (National Institutes of Health). In vitro transcription was performed at 37°C for 2 h in a 25-μl volume containing 40 mM Tris, pH 7.9; 6 mM MgCl2; 2 mM dithiothreitol (DTT); 40 U of RNase inhibitor (Promega, Madison, WI); 400 μM each of ATP, GTP, and UTP; 10 μM [35S]CTP (800 Ci/mmol, Amersham Corp., Arlington Heights, IL); 1 μg of linearized plasmid; and 20 U of RNA polymerase (Promega). After transcription, the DNA template was removed by digestion with RNase-free DNase (Promega Biotec) for 30 min at 37°C, and the transcripts were size reduced to 150 to 250 nucleotides by alkali treatment with 0.2 N NaOH for 45 min on ice. The probes then were extracted with phenol/chloroform/isooamyl alcohol (25:24:1), and the unincorporated nucleotides were removed by fractionation on a G5 Sephadex Nick column (Pharmacia, Piscataway, NJ).

Pretreatment of the slide-mounted sections included fixation in buffered 4% formaldehyde for 15 min at room temperature followed by a 5-min rinse in 0.1 M phosphate-buffered saline. Slides were treated with 0.25% acetic anhydride in 0.1 M triethanolamine-HCl/0.15 M NaCl (pH 8.0) for 10 min and rinsed in 2× standard saline citrate (SSC; 0.15 M NaCl, 0.015 M sodium citrate). Sections then were dehydrated in graded ethanol followed by two 5-min incubations in chloroform. One-minute incubations in 100% and 95% ethanol were followed by air drying.

Slides were hybridized with 100 μl of buffer containing 7.5 ng of cRNA probe in 50% formamide, 0.75 M NaCl, 20 mM 1,4-piperazine diethane sulfonic acid, pH 6.8, 10 mM EDTA, 10% dextran sulfate, 5× Denhardt’s solution (0.02% bovine serum albumin, 0.02% Ficoll, 0.02% polyvinylpyrrolidone), 50 mM DTT, 0.2% sodium dodecyl sulfate, and 100 μg/ml each salmon sperm DNA and yeast tRNA. Slides were coverslipped, sealed with Royalbond Grip contact cement, and hybridized for 16 h at 50°C.

After hybridization, coverslips were removed in 4× SSC plus 300 mM 2-mercaptoethanol at room temperature, incubated in this solution for 15 min, and incubated in 4× SSC without 2-mercaptoethanol for 15 min at room temperature. Slides were treated with 1:1 formamide-buffer (0.6 M NaCl, 40 mM Tris base, 2 μM EDTA, 20 mM HCl) at 60°C for 20 min followed by a 5-min rinse in room temperature 2× SSC. Sections then were treated with 50 μg/ml pancreatic RNase A in 0.5 M NaCl, 50 mM Tris pH 8.0, and 5 mM EDTA for 30 min at 37°C, washed in graded salt solutions (2×, 1×, and 0.5× SSC each for 5 min at room temperature), with a final wash in 0.1× SSC at 65°C for 30 min. Slides then were cooled to room temperature in 0.1× SSC, dipped in 60% ethanol with 0.3 M ammonium acetate, and air dried. Sections were exposed to X-ray film (DuPont Cronex) for 8 to 96 h and subsequently dipped in Kodak NTB-2 photographic emulsion (diluted 1:2 with D3H2O), exposed at 4°C, and developed in Kodak D-19 developer.

Quantitative analyses were performed using NIH Image software on captured darkfield images of the emulsion-dipped sections. Images of representative areas from each brain were captured at 40×
magnification. Silver grain densities in the Purkinje cell were determined in boxes of 900 μm²; cerebellar granule cells were assessed in 8100-μm² boxes; nucleus of the brachium of the inferior colliculus and thalamic nuclei were assessed in 112,000-μm² boxes; all other regions were assessed in 225,000-μm² boxes. Data were analyzed by two-way analysis of variance (ANOVA) or by Student’s t test where appropriate.

**Induction of Dystonia in Tottering Mutant Mice.** Intermittent dystonic episodes in tottering mutant mice are inducible. For all experiments assessing the effects of calcium channel blockers on tottering mouse motor episodes, adult mice were transported daily from the vivarium to the laboratory and acclimated for at least 4 h. The extensive acclimation period provided sufficient recovery time for tottering mutants, which routinely express dystonia upon transport. Mice then were injected with vehicle or drug and placed back in the home cage for 30 min. To induce dystonic episodes after drug treatment, mice were restrained in a 60-ml syringe for 10 min, released into a novel plastic cage for 30 min, then returned to the home cage. The mice were scored for the presence or absence of dystonia from the time of injection until 10 min after return to the home cage, a total of 80 min.

**Intracerebroventricular Injections of L-Type Calcium Channel Blockers.** At least 4 h after transport to the laboratory, tottering mutant mice were anesthetized with methoxyflurane (Pittman-Moore, Inc., Mundelein, IL). After anesthetization (3–3.5 min in methoxyflurane), a small slit was made at the base of the skull and a 27-gauge syringe needle, blunted to a length of 5 mm, was inserted at the midline between the skull and first vertebra. Saline vehicle or drug was injected directly into the fourth ventricle in a volume of 5 μl. Drug masses tested were diltiazem (20 μg) and verapamil (10 μg). All drugs were dissolved in saline. Dihydropyridines were not used i.e.v. because they are relatively insoluble; the vehicle in which dihydropyridines could be solubilized for s.c. administration caused massive intracerebral bleeding, prohibiting the use of these drugs i.e.v. Mice recovered from the anesthesia within 15 min. Thirty minutes after injection, the mice were subjected to the dystonia-induction paradigm described above. All mice were sacrificed imme-

![Fig. 1. Effect of s.c. injection of the dihydropyridine class of L-type calcium channel blockers on restraint-induced dystonia in tottering mutant mice. A, nimodipine prevented tottering mouse dystonia in a dose-dependent manner. Doses of 1 mg/kg and above significantly reduced the frequency of dystonic events, completely preventing the events at 10 and 20 mg/kg. B, nifedipine also prevented tottering mouse dystonia in a dose-dependent manner. The effect reached statistical significance at doses of 5 and 20 mg/kg. C, nitrendipine significantly reduced the occurrence of restraint-induced tottering mouse dystonia at doses of 5, 10, and 20 mg/kg. Nitrendipine was completely protective at 20 mg/kg. Data represent mean ± S.E.M. (n = 5–6). For each drug, values that are significantly less than vehicle as determined by one-way ANOVA followed by Dunnett t test are denoted by ** (P < .01) and * (P < .05).](molpharm.aspetjournals.org)
diately after the observation period. Data were analyzed by one-way ANOVA followed by Dunnett t test.

Subcutaneous Injections of L-Type Calcium Channel Blockers and Activators. The L-type calcium channel blockers nimodipine, nifedipine, nitrendipine, diltiazem, and verapamil were injected s.c. into tottering mutant mice in a volume of 5 ml/kg. Groups of five to six tottering mice were used for each dose-response analysis with five trials at each drug concentration. Mice were injected and challenged in the dystonia induction paradigm (see above) once daily for 5 consecutive days at each dose. The order of drug doses was randomized for each mouse. The mice were allowed 2 days of recovery between drug doses when progressing to a higher dose; 9 days elapsed before treatment with a lower dose of drug. Data were analyzed by one-way factorial ANOVA followed by Dunnett t tests comparing the response at each drug dose with vehicle.

To assay the effects of s.c. injection of the L-type calcium channel activator Bay K8644 on tottering mouse dystonia, five tottering mutant females and five age-matched C57BL/6J-+/+ control females (5–7 months of age) were transported to the laboratory daily. After a period of acclimation of at least 4 h, Bay K8644 or vehicle at a volume of 5 ml/kg was injected s.c. The mice were returned directly to the home cage and observed for 60 min with no attempts to induce the motor episodes environmentally. The mice were injected with vehicle on the first day followed by increasing doses of Bay K8644 on subsequent consecutive days. Data were analyzed by one-way factorial ANOVA followed by Dunnett t tests comparing the response at each drug concentration with vehicle.

[^3H]Nitrendipine-Binding Assays. Tottering (tg/tg) mutant mice and gender-matched normal (+/+) controls 2 to 3 months of age were deeply anesthetized with carbon dioxide and decapitated. The brains were removed rapidly, dissected into cerebellum and forebrain, discarded brainstem and olfactory bulbs, and frozen at −70°C until use. Tissues were homogenized in 100 volumes of ice-cold 50 mM Tris-HCl buffer (pH 7.4) with a Tekmar tissue homogenizer (Cincinnati, OH) at setting 70. The homogenates were centrifuged at 30,000g for 10 min, and the supernatant was discarded. Pellets were resuspended in ice-cold buffer and centrifuged again at 30,000g for 10 min. Pellets were resuspended to 25 mg wet weight tissue/ml buffer (forebrain) or 50 mg/ml buffer (cerebellum). Protein concentrations were determined with the Pierce (Rockford, IL) BCA protein assay.

Binding assays were performed in a total volume of 2 ml in 50 mM Tris-HCl buffer for 90 min at 22°C (Marangos et al., 1982). Each reaction contained either 5 mg/ml (cerebellum) or 2.5 mg/ml (forebrain) tissue. Six concentrations of[^3H]nitrendipine (78.5 Ci/mmol) ranging from 20 to 1000 pM defined total binding; nonspecific binding was determined in the presence of 1 μM nifedipine. Reactions were terminated by rapid filtration over Whatman GF/C filters, which were washed rapidly three times with 3 ml of ice-cold buffer. Filters were allowed to dry and then were placed in ScintiVerse (Fisher) scintillation fluid. Radioactivity was determined by liquid scintillation spectroscopy at an efficiency of 35 to 40%. Data were analyzed using GraphPad Prism 2.0 software.

Results

Effect of Bay K8644 on Tottering Mouse Dystonic Episodes. Tottering mouse dystonia and the seizures induced by the L-type calcium channel activator Bay K8644 in normal mice are behaviorally distinct. In contrast to the stereotypic spastic contractions and extensions that characterize the tottering mouse phenotype, Bay K8644-induced seizures in normal mice are characterized by a stiff tail, arched back, squeaking, forelimb and hindlimb clonus, flexion and extension of hindlimbs, jumping, catatonia, and loss of righting reflex (Palmer et al., 1993).

Bay K8644 did not induce seizures in control (C57BL/6J-+/+) mice at concentrations below 10 mg/kg (Table 1). At 10 mg/kg the characteristic Bay K8644 seizure was observed in all normal controls. In tottering mutants, although dystonia was not observed after vehicle injection, 40% of the mice exhibited stereotypical tottering mouse dystonic events in response to a 1-mg/kg dose of the L-type calcium channel activator. Bay K8644 induced dystonia in 100% of tottering mutant mice at a dose of 2 mg/kg. The dystonic episodes induced by 2 mg/kg Bay K8644 were behaviorally indistinguishable from restraint-induced tottering mouse dystonia with an average latency to onset of 22 ± 6 (mean ± S.E.M.) min. A dose of 5 mg/kg in tottering mutants induced stereotypical tottering mouse dystonic events accompanied by occasional squeaking, the first characteristic of Bay K8644-induced seizures observed in tottering mice. Other characteristics of Bay K8644 induced seizures, specifically jumping and catatonia, were observed in tottering mutants after a 5 mg/kg dose, but these were not observed until after the tottering mouse dystonic episodes were complete. Tottering mutants treated with 10 mg/kg Bay K8644 expressed stereotypical tottering mouse dystonia with an average latency of 3.7 ± 0.3 min. This highest dose also produced more of the characteristics of Bay K8644 seizures in tottering mutants: the mice vocalized, jumped, and exhibited catatonia. In summary, mutants demonstrated stereotypical dystonic episodes at every dose tested with additional characteristics of Bay K8644 seizures observed at 5 and 10 mg/kg, and
the latency to expression of dystonia in tottering mutants decreased with increasing concentration of drug.

**Effect of Subcutaneous Injection of L-Type Calcium Channel Blockers on Tottering Mouse Dystonic Episodes.** The dihydropyridines nimodipine, nitrendipine, and nifedipine each prevented restraint-induced tottering mouse dystonia in a dose-dependent manner (Fig. 1). Nimodipine significantly reduced the occurrence of these episodes at 1, 5, 10, and 20 mg/kg and was completely protective against tottering mouse dystonia at 10 and 20 mg/kg. Nifedipine and nitrendipine each significantly prevented the expression of the movement disorder at 5, 10, and 20 mg/kg. Nitrendipine was completely protective at 20 mg/kg. Even the highest doses of dihydropyridines tested caused no observable side-effects: the mice were active and the ataxia of tottering mice was not noticeably altered.

The benzothiazepine diltiazem also prevented the tottering mouse motor episodes in a dose-dependent fashion (Fig. 2). The ability of diltiazem to block the dystonia reached significance at 20 and 40 mg/kg. No behavioral side-effects were observed at 20 mg/kg. However, tottering mutant mice injected with 40 mg/kg diltiazem exhibited severe side-effects: the mice were reproducibly inactive, sitting in the corner of the cage for several hours; when provoked to move, these mice exhibited markedly severe ataxia, which subsided several hours after injection.

Injection of the phenylalkylamine verapamil, s.c., had no effect on the tottering mouse phenotype at sublethal doses (Fig. 3). Doses of verapamil of 10 mg/kg or greater were reproducibly lethal in both tottering mutants and normal (C57BL/6J+/t) controls. Verapamil is a specific L-type calcium channel blocker but does not cross the blood-brain barrier in appreciable quantities (Hamann et al., 1983).

**Effect of Intracerebroventricular Injection of L-Type Calcium Channel Blockers on Tottering Mouse Dystonic Episodes.** Tottering mutant mice injected i.c.v. with saline vehicle exhibited dystonic events in 64% of trials (Table 2). The L-type calcium channel blocker diltiazem eliminated the motor episodes when injected i.c.v., similar to s.c. injection. The phenylalkylamine verapamil, which does not cross the blood-brain barrier and failed to prevent tottering mouse dystonia upon s.c. injection, significantly reduced the frequency of the episodes in tottering mutant mice to 20% when administered i.c.v. (Table 2). Thus, injection of L-type calcium channel blockers directly into the central nervous system effectively prevented the intermittent dystonic episodes exhibited by tottering mutant mice.

**L-Type Calcium Channel α1C and α1D Subunit mRNA Expression.** Consistent with previous reports (Tanaka et al., 1995), the calcium channel α1C subunit mRNA was expressed throughout the brain including cerebral cortex, thalamus, hippocampus, and cerebellum (Fig. 4). Quantitative analyses of grain density in parasagittal brain sections from

---

**TABLE 1**

Frequency and latency of Bay K8644-induced seizures in control (C57BL/6J+/+) mice and dystonia in tottering (C57BL/6J-tg/tg) mice

<table>
<thead>
<tr>
<th>Bay K8644 Dose</th>
<th>Control Mice</th>
<th>Tottering Mutants</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Seizure Frequency</td>
<td>Latency (min)</td>
</tr>
<tr>
<td>Vehicle</td>
<td>0%</td>
<td>0%</td>
</tr>
<tr>
<td>1 mg/kg</td>
<td>0%</td>
<td></td>
</tr>
<tr>
<td>2 mg/kg</td>
<td>0%</td>
<td></td>
</tr>
<tr>
<td>5 mg/kg</td>
<td>0%</td>
<td></td>
</tr>
<tr>
<td>10 mg/kg</td>
<td>100%*</td>
<td>29 ± 3</td>
</tr>
</tbody>
</table>

* P < .01 from vehicle control by ANOVA followed by Dunnett’s test.

**TABLE 2**

Ability of L-type calcium channel blockers injected i.c.v. to prevent restraint-induced tottering mouse dystonic episodes

<table>
<thead>
<tr>
<th>Drug Injection, i.c.v.</th>
<th>% Tottering Mice Exhibiting Dystonia</th>
</tr>
</thead>
<tbody>
<tr>
<td>Saline vehicle</td>
<td>64% (n = 11)</td>
</tr>
<tr>
<td>Verapamil, 10 µg</td>
<td>20%* (n = 10)</td>
</tr>
<tr>
<td>Diltiazem, 20 µg</td>
<td>0%* (n = 6)</td>
</tr>
</tbody>
</table>

* P < .05 versus saline vehicle control by ANOVA followed by Dunnett’s t-test.

**Fig. 3.** Effect of s.c. injection of the phenylalkylamine verapamil on tottering mouse dystonia. Verapamil had no effect on the frequency of dystonic events by this route of administration (ANOVA, P > 0.50). Doses of 10 mg/kg or greater were invariably lethal in both tottering mutants and C57BL/6J+/+ controls. Although the drug is a potent L-type calcium channel blocker, verapamil does not cross the blood-brain barrier efficiently. Data represent mean ± S.E.M. (n = 5).

**Fig. 4.** Darkfield photomicroscopy of in situ hybridization for calcium channel α1C subunit mRNA expression in control and tottering mice. The α1C subunit calcium channel gene was expressed predominantly in thalamus, cortex, and cerebellum. A, photomicrograph (magnification, 0.7×) of sagittal +/+ and tg/tg brain sections. B, photomicrograph (magnification, 5×) of the cerebellum of the section shown in A.
control (+/+ ) and tottering (tg/tg) mice (n = 3 per genotype) revealed a significant increase in the expression of calcium channel α1C subunit mRNA in Purkinje cells of the cerebellum in tottering mice (Table 3). Quantitation was performed on Purkinje cells from both Lobule V and Lobule VIII; in both lobules, expression of the α1C subunit was increased significantly in tottering mice. In fact, α1C subunit mRNA is expressed at extremely low levels in Purkinje cells of control mice, but expressed abundantly in Purkinje cells of tottering mice (Fig. 4). However, α1C subunit mRNA was not increased equally in all Purkinje cells whereby a dramatic increase in expression was observed in some cells but little increase in expression was observed in others (Fig. 4). In contrast, calcium channel α1C subunit mRNA expression was comparable in cerebellar granule cells and deep cerebellar nuclei in control and tottering mice (Table 3), indicating a cell-type-specific regulation of the α1C subunit resulting from the calcium channel α1A subunit mutation. A significant increase in α1C subunit mRNA also was observed in the nucleus of the brachium of the inferior colliculus in tottering mice whereas thalamic nuclei, hippocampus, and olfactory bulb expression did not significantly differ from control mice (Table 3). Although an increase in α1C subunit expression was observed in the cortex, this trend did not reach significance (P < .1).

The calcium channel α1D subunit was expressed throughout brain, similar to the α1C subunit, but with abundant Purkinje cell expression observed in both control and tottering mice (data not shown); α1D subunit mRNA distribution was as described in previous reports (Tanaka et al., 1995). The α1D subunit was not expressed in the nucleus of the brachium of the inferior colliculus where a significant increase in α1C subunit mRNA expression was observed. Quantitative analyses of grain density in parasagittal brain sections demonstrated that α1D subunit expression was similar in control (+/+ ) and tottering (tg/tg) mice (n = 3 per genotype; Table 4).

P/Q-Type Calcium Channel α1A Subunit mRNA Expression. The calcium channel α1A subunit mRNA was expressed in the cerebellum, inferior colliculus, and hippocampus as described in previous reports (Tanaka et al., 1995; Fletcher et al., 1996; data not shown). Hippocampal expression appeared uniform throughout the dentate gyrus and the cornu ammonos subdivisions. The calcium channel α1A subunit mRNA expression was most abundant in cerebellar cortex with high levels in cerebellar granule cells and Purkinje cells.

Quantitative analyses of grain density in parasagittal brain sections from control (+/+ ), heterozygous (+/tg), and tottering (tg/tg) mice (n = 3 per genotype) were performed in the cerebellum, where an increase in α1C subunit mRNA expression was observed. Grain densities in four to six representative high-power section images from individual cerebellar lobules (III–X) of each genotype were analyzed. A two-way factorial ANOVA indicated no significant differences among the three genotypes in either the Purkinje cell (ANOVA, P > 0.24) or granule cell (ANOVA, P > 0.86) layers. Similarly, no significant differences among lobules were observed in Purkinje cells (ANOVA, P > 0.25) and no genotype-by-lobule interaction was observed in either the Purkinje cell (ANOVA, P > 0.95) or granule cell (ANOVA, P > 0.62) layers. Although a significant effect of lobule in the granule cell layer was suggested by the two-way ANOVA (P < .02), a posthoc Scheffe F-test revealed no significant differences among the mean grain densities (P > .05). Thus, the tottering mutation does not affect expression of the calcium channel α1A subunit mRNA within cerebellar lobules III through X.

Discussion

These data suggest that 1-type calcium channels are up-regulated in response to the mutation in the P/Q-type calcium channel in tottering mice. Furthermore, 1-type calcium channels appear to influence the expression of the intermittent dystonic episodes in tottering mice. The tg mutation directly alters the mouse calcium channel α1A subunit gene.

### Table 3

Quantitative analysis of calcium channel α1C subunit mRNA expression in control (+/+ ) and tottering (tg/tg) mouse brain

<table>
<thead>
<tr>
<th>Brain Region</th>
<th>+/-</th>
<th>tg/tg</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cerebellar Purkinje cell layer (Lobule VIII)</td>
<td>110.6 ± 3.6 (11)</td>
<td>132.6 ± 3.6 (11)**</td>
</tr>
<tr>
<td>Cerebellar granule cell layer (Lobule VIII)</td>
<td>107.6 ± 3.7 (11)</td>
<td>110.4 ± 4.3 (11)</td>
</tr>
<tr>
<td>Deep cerebellar nuclei</td>
<td>88.5 ± 1.7 (11)</td>
<td>74.3 ± 2.0 (11)</td>
</tr>
<tr>
<td>Nucleus of the brachium of the inferior colliculus</td>
<td>80.3 ± 3.5 (7)</td>
<td>98.3 ± 4.4 (6)*</td>
</tr>
<tr>
<td>Medial geniculate nucleus</td>
<td>75.8 ± 2.7 (10)</td>
<td>83.3 ± 4.4 (9)</td>
</tr>
<tr>
<td>Thalamic ventrobasal complex</td>
<td>73.0 ± 2.5 (11)</td>
<td>78.2 ± 3.1 (10)</td>
</tr>
<tr>
<td>Hippocampal dentate gyrus</td>
<td>59.1 ± 2.1 (11)</td>
<td>58.9 ± 2.5 (11)</td>
</tr>
<tr>
<td>Cerebral cortex</td>
<td>57.5 ± 3.3 (11)</td>
<td>67.2 ± 3.8 (11)</td>
</tr>
<tr>
<td>Olfactory bulb</td>
<td>83.5 ± 4.9 (11)</td>
<td>78.8 ± 4.1 (11)</td>
</tr>
</tbody>
</table>

* P < .01 and ** P < .001 as determined by two-tailed Student's t test.
which encodes the pore-forming protein of P/Q-type calcium channels. Diffusible P/Q-type calcium channel blockers currently are unavailable, and, as such, the role of the mutant P/Q-type calcium channel in the expression of the motor phenotype is unclear at this time. However, pharmacologic blockade of L-type calcium channels with several distinct agents prevented tottering mouse dystonia. Additionally, L-type calcium channel mRNA expression and binding was increased in tottering mice. The increase in L-type calcium channels coupled with the ability of L-type channel blockers to prevent the intermittent dystonic episodes suggest that L-type calcium channels play a role in the abnormal motor phenotype expressed by tottering mutant mice.

Several agents that specifically alter L-type calcium channel activity affected the behavioral expression of the tottering mouse dystonic episodes. L-type calcium channel antagonists of the dihydropyridine class, nimodipine, nifedipine, and nitrendipine, prevented restraint-induced dystonia in a dose-dependent manner. Diltiazem, an L-type calcium channel blocker of the benzothiazepine class, prevented restraint-induced dystonia when injected either s.c. or i.c.v. The dihydropyridines and diltiazem cross the blood-brain barrier efficiently (Naito et al., 1986; Larkin et al., 1992), and both drug types bind extracellular sites on L-type calcium channels involving the S6 segments of repetitive domains III and IV (Kraus et al., 1996; Peterson et al., 1996). The binding sites appear allosterically linked but distinct because diltiazem enhances the binding of dihydropyridines (Yamamura et al., 1982). The phenylalkylamine verapamil also prevented dystonia when injected i.c.v.; the phenylalkylamine-binding site on L-type calcium channels is clearly distinct from the dihydropyridine and benzothiazepine sites, involving an intracellular site between S6 of repetitive domain IV and the C-terminal tail (Striessnig et al., 1990). Thus, five different L-type calcium channel blockers from three different drug classes all prevented the expression of the dystonic phenotype attesting to the specificity of the effect.

The ability of verapamil to prevent tottering mouse dystonia when injected i.c.v. underscores the role of central nervous system L-type calcium channel blockade in the prevention of this phenotype. The same drug injected peripherally failed to prevent dystonia in tottering mice at sublethal concentrations. Verapamil, a potent and specific L-type calcium channel antagonist, does not cross the blood-brain barrier in appreciable amounts (Hamann et al., 1983). The differential effects of the drug injected via two different routes indicates that blockade of peripheral L-type calcium channels in cardiac and skeletal muscle, where L-type calcium channels are the predominant carriers of calcium current, is insufficient to prevent dystonia. These data suggest that L-type calcium channel blockers prevent the tottering mouse motor abnormalities by acting within the central nervous system rather than on cardiac or skeletal muscle.

Activation of L-type calcium channels with the dihydropyridine Bay K8644 induced stereotypical tottering mouse dys-

---

**TABLE 4**

Quantitative analysis of calcium channel α1D subunit mRNA expression in control (+/+) and tottering (tg/tg) mouse brain

Data represent mean ± S.E.M. (n = 3) with number of sections assessed in parentheses. Quantitative analysis of calcium channel α1D subunit mRNA expression were not observed as determined by two-tailed Student’s t test. No detectable (N.D.) hybridization was observed in the nucleus of the brachium of the inferior colliculus.

<table>
<thead>
<tr>
<th>Brain Region</th>
<th>+/+</th>
<th>tg/tg</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cerebellar Purkinje cells (Lobule VIII)</td>
<td>151.0 ± 7.0 (9)</td>
<td>151.7 ± 7.6 (9)</td>
</tr>
<tr>
<td>Cerebellar granule cell layer (Lobule VIII)</td>
<td>152.9 ± 8.9 (9)</td>
<td>146.5 ± 5.9 (9)</td>
</tr>
<tr>
<td>Deep cerebellar nuclei</td>
<td>71.5 ± 3.1 (9)</td>
<td>68.0 ± 2.6 (9)</td>
</tr>
<tr>
<td>Nucleus of the brachium of the inferior colliculus</td>
<td>N.D.</td>
<td>N.D.</td>
</tr>
<tr>
<td>Medical geniculate nucleus</td>
<td>75.2 ± 3.4 (8)</td>
<td>68.8 ± 5.2 (6)</td>
</tr>
<tr>
<td>Thalamic ventrobasal complex</td>
<td>69.9 ± 2.2 (9)</td>
<td>71.2 ± 4.0 (8)</td>
</tr>
<tr>
<td>Hippocampal dentate gyrus</td>
<td>77.2 ± 2.7 (9)</td>
<td>73.4 ± 3.9 (9)</td>
</tr>
<tr>
<td>Cortex</td>
<td>87.0 ± 4.4 (9)</td>
<td>78.1 ± 5.4 (9)</td>
</tr>
<tr>
<td>Olfactory bulb</td>
<td>109.0 ± 4.1 (9)</td>
<td>99.4 ± 6.0 (9)</td>
</tr>
</tbody>
</table>

---

**TABLE 5**

Equilibrium dissociation constant, Kd (in pM), and number of binding sites, Bmax (in fmol/mg protein), for [3H]nitrendipine saturation binding in control (+/+) and tottering (tg/tg) mouse brain.

The number of [3H]nitrendipine-binding sites was increased in tottering mouse cerebellum. Data are expressed as mean ± S.E.M. of three to five experiments.

<table>
<thead>
<tr>
<th>Cerebellum</th>
<th>Forebrain</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kd pM</td>
<td>Bmax fmol/mg protein</td>
</tr>
<tr>
<td>+/+</td>
<td>197 ± 40</td>
</tr>
<tr>
<td>tg/tg</td>
<td>203 ± 42</td>
</tr>
</tbody>
</table>

* P < .05 versus control (+/+) Bmax by two-tailed Student’s t test.
tonia at low doses and seizures more typical of this drug at higher doses. The two different disorders induced by Bay K8644 in tottering mice presumably result from regionally distinct calcium channel activation. In a tottering mouse, the dystonia may be induced at low doses through up-regulated \(L\)-type calcium channels. Specific increases in calcium channel \(\alpha_{1C}\) subunit mRNA were observed in cerebellar Purkinje cells and the nucleus of the brachium of the inferior colliculus. As the dose of Bay K8644 is increased, the “classical” Bay K8644 seizures likely were induced through normosensitive \(L\)-type calcium channels located elsewhere in brain. This also would explain why wild-type mice injected with Bay K8644 do not exhibit tottering-like motor abnormalities as the up-regulated expression of \(\alpha_{1C}\) subunits is required for expression of dystonia.

\(P/Q\)-type calcium channels are expressed throughout brain with the highest expression levels corresponding to regions of high cell density including cerebellar cortex, hippocampus, and olfactory bulb (Stea et al., 1994; Tanaka et al., 1995; Volsen et al., 1995). Thus, any compensatory changes in calcium channel expression may be more evident in cerebellar cortex, but it is not clear why \(L\)-type calcium channels are not increased in other brain regions that express high levels of \(P/Q\)-type calcium channels. Consistent with the mRNA expression patterns, \(P/Q\)-type calcium channel currents predominate in cultured rat cerebellar cortex neurons, carrying 85 to 95% of the total calcium current in Purkinje cells (Mintz et al., 1992) and nearly half the calcium current in granule cells (Randall and Tsien, 1995). In contrast, \(L\)-type currents account for a small fraction of the total current (~20%) in both cell types. Thus, an increase in \(L\)-type calcium channels could lead to a dramatic change in the conductance of calcium ions in these neurons. The potential for dramatic functional effects is particularly evident in Purkinje cells where \(L\)-type channels are restricted to the soma and proximal dendrites (Hell et al., 1993) and thus are positioned to have greater influence on the axon hillock than would be expected by a random distribution.

Although the functional significance of the tottering mutation on \(P/Q\)-type calcium channels is as yet unknown, functional differences between \(L\)-type and \(P/Q\)-type calcium channels are well characterized. In experiments directly comparing \(\alpha_{1A}\) (\(P/Q\)-type) and \(\alpha_{1C}\) (\(L\)-type) calcium channels under standard conditions, Sather et al. (1993) found that the single-channel conductance of \(\alpha_{1C}\) channels is measurably greater than that of \(\alpha_{1A}\) channels; the same is true of native \(L\)-type channels compared with native \(P/Q\)-type channels. Both \(L\)-type and \(P/Q\)-type calcium channel currents can be facilitated by a prepulse (Bourinet et al., 1994), with \(P/Q\)-type currents facilitated by relief of G-protein-mediated inhibition (Currie and Fox, 1997). The facilitated \(L\)-type currents can be very large (more than three times the control currents) and are inducible by either a single strong depolarization or a short train of pulses (Bourinet et al., 1994), whereas the facilitation of \(P/Q\)-type currents is more subtle, with only ~18% of the inhibition being voltage-sensitive (Currie and Fox, 1997). This facilitation of \(L\)-type calcium currents may explain how \(L\)-type calcium channel expression promotes the expression of intermittent dystonia in tottering mice. It is possible that temporal summation of calcium influx through voltage-dependent calcium channels, blunted in normal mice by a paucity of facilitation-susceptible \(L\)-type calcium channels, may be augmented by the increased density of \(L\)-type channels in tottering mutants.

Mutations of the calcium channel \(\alpha_{1A}\) subunit are associated with three distinct human diseases and two distinct mouse neurologic phenotypes. The human spinocerebellar ataxia type 6 (SCA6) and mouse leaner (tg\(^{12}\)) mutations both disrupt the intracellular carboxyl tail of the calcium channel (Fletcher et al., 1996; Zhuchenko et al., 1997) and cause a persistent debilitating ataxia associated with severe degeneration of cerebellar neurons (Herrup and Wilczynski, 1982; Zhuchenko et al., 1997). In contrast, the human disorders familial hemiplegic migraine (FHM) and episodic ataxia type-2 (EA-2) mutations as well as the mouse tottering (tg) mutation alter the transmembrane and/or pore regions of the channel (Fletcher et al., 1996; Ophoff et al., 1996) and cause episodic attacks of neurologic dysfunction with little or no obvious changes in cerebellar morphology (Isaacs and Abbott, 1994; von Brederlow et al., 1995; Terwindt et al., 1996). FHM is characterized by brief periods of hemiparesis or weakness accompanied by migraine headaches. EA-2 patients exhibit intermittent attacks of ataxia precipitated by stress or exercise. The genotypic and phenotypic similarities between these human diseases and the intermittent motor phenotype of tottering mutant mice suggest the tottering mouse is a useful model for determining how mutations of the calcium channel \(\alpha_{1A}\) subunit can generate episodic neurologic dysfunction in humans. Furthermore, tottering mice are an important tool for determining cell-type-specific regulation of calcium channel subtype expression and function in mammalian brain.

Acknowledgments
We thank Jesse B. North and Hehui Li for technical assistance and Dr. H. A. Jinnah and Brandy E. Fureman for helpful discussion.

References

**Send reprint requests to:** Ellen J. Hess, Ph.D., Department of Neuroscience and Anatomy, Pennsylvania State University College of Medicine, 500 University Drive, Hershey, PA 17033. E-mail: ehess@psu.edu